Literature DB >> 20041443

Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice.

Florian Krammer1, Sabine Nakowitsch, Paul Messner, Dieter Palmberger, Boris Ferko, Reingard Grabherr.   

Abstract

Recent outbreaks of influenza A highlight the importance of rapid and sufficient supply for pandemic and inter-pandemic vaccines. Classical manufacturing methods for influenza vaccines fail to satisfy this demand. Alternatively, cell culture-based production systems and virus-like particle (VLP)-based technologies have been established. We developed swine-origin pandemic H1N1 influenza VLPs consisting of hemagglutinin (A/California/04/2009) and matrix protein. Hemagglutinin and matrix protein were co-expressed in insect cells by the baculovirus expression system. VLPs were harvested from infection supernatants, purified and used for intraperitoneal immunization of BALB/c mice. Immunization induced high serum antibody titers against A/California/04/2009 as well as hemagglutination inhibiting antibodies. Additionally, we compared VLP production in two different insect cell lines, Sf9 and BTI-TN5B1-4 (High Five). Taken together VLPs represent a potential strategy for the fight against new pandemic influenza viruses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20041443      PMCID: PMC4388400          DOI: 10.1002/biot.200900267

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  27 in total

1.  Screening of insect cell lines for the production of recombinant proteins and infectious virus in the baculovirus expression system.

Authors:  T J Wickham; T Davis; R R Granados; M L Shuler; H A Wood
Journal:  Biotechnol Prog       Date:  1992 Sep-Oct

2.  Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus.

Authors:  Fu-Shi Quan; Chunzi Huang; Richard W Compans; Sang-Moo Kang
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

3.  Recombinant baculovirus isolation.

Authors:  Linda A King; Richard Hitchman; Robert D Possee
Journal:  Methods Mol Biol       Date:  2007

Review 4.  Baculoviral vectors for gene delivery: a review.

Authors:  Yu-Chen Hu
Journal:  Curr Gene Ther       Date:  2008-02       Impact factor: 4.391

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

Authors:  Rick A Bright; Donald M Carter; Shannon Daniluk; Franklin R Toapanta; Attiya Ahmad; Victor Gavrilov; Mike Massare; Peter Pushko; Nutan Mytle; Thomas Rowe; Gale Smith; Ted M Ross
Journal:  Vaccine       Date:  2007-02-15       Impact factor: 3.641

7.  Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.

Authors:  Marc-André D'Aoust; Pierre-Olivier Lavoie; Manon M-J Couture; Sonia Trépanier; Jean-Martin Guay; Michèle Dargis; Sébastien Mongrand; Nathalie Landry; Brian J Ward; Louis-P Vézina
Journal:  Plant Biotechnol J       Date:  2008-12       Impact factor: 9.803

8.  H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

Authors:  Kutubuddin Mahmood; Rick A Bright; Nutan Mytle; Donald M Carter; Corey J Crevar; Jenna E Achenbach; Penny M Heaton; Terrence M Tumpey; Ted M Ross
Journal:  Vaccine       Date:  2008-08-14       Impact factor: 3.641

Review 9.  Influenza vaccines based on virus-like particles.

Authors:  Sang-Moo Kang; Jae-Min Song; Fu-Shi Quan; Richard W Compans
Journal:  Virus Res       Date:  2009-04-15       Impact factor: 3.303

10.  Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge.

Authors:  Lucy A Perrone; Attiya Ahmad; Vic Veguilla; Xiuhua Lu; Gale Smith; Jacqueline M Katz; Peter Pushko; Terrence M Tumpey
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

View more
  17 in total

Review 1.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

2.  Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines.

Authors:  Florian Krammer; Theresa Schinko; Dieter Palmberger; Christopher Tauer; Paul Messner; Reingard Grabherr
Journal:  Mol Biotechnol       Date:  2010-07       Impact factor: 2.695

3.  Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis.

Authors:  Florian Krammer; Theresa Schinko; Paul Messner; Dieter Palmberger; Boris Ferko; Reingard Grabherr
Journal:  J Virol Methods       Date:  2010-03-19       Impact factor: 2.014

4.  Characterization of Coxsackievirus B4 virus-like particles VLP produced by the recombinant baculovirus-insect cell system expressing the major capsid protein.

Authors:  Ikbel Hadj Hassine; Jawhar Gharbi; Bechr Hamrita; Mohammed A Almalki; José Francisco Rodríguez; Manel Ben M'hadheb
Journal:  Mol Biol Rep       Date:  2020-04-02       Impact factor: 2.316

5.  All-in-one bacmids: an efficient reverse genetics strategy for influenza A virus vaccines.

Authors:  Hongjun Chen; Matthew Angel; Weizhong Li; Courtney Finch; Ana Silvia Gonzalez; Troy Sutton; Jefferson Santos; Daniel R Perez
Journal:  J Virol       Date:  2014-06-18       Impact factor: 5.103

6.  A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo.

Authors:  Gene S Tan; Florian Krammer; Dirk Eggink; Alita Kongchanagul; Thomas M Moran; Peter Palese
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

7.  Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity.

Authors:  Irina Margine; Luis Martinez-Gil; Yi-Ying Chou; Florian Krammer
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

Review 8.  MultiBac turns sweet.

Authors:  Dieter Palmberger; Miriam Klausberger; Imre Berger; Reingard Grabherr
Journal:  Bioengineered       Date:  2012-03-01       Impact factor: 3.269

9.  A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies.

Authors:  Anthony J S Chua; Cyrielle Vituret; Melvin L C Tan; Gaëlle Gonzalez; Pierre Boulanger; Mah-Lee Ng; Saw-See Hong
Journal:  Virol J       Date:  2013-04-24       Impact factor: 4.099

Review 10.  Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches.

Authors:  Christine M Thompson; Emma Petiot; Alexandre Lennaertz; Olivier Henry; Amine A Kamen
Journal:  Virol J       Date:  2013-05-04       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.